Anrikefon - Sichuan Haisco Pharmaceutical
Alternative Names: HSK-21542; SisoojingLatest Information Update: 25 Aug 2026
At a glance
- Originator Sichuan Haisco Pharmaceutical
- Class Antiemetics; Antipruritics; Opioid analgesics; Peptides; Skin disorder therapies; Small molecules
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Postoperative pain; Pruritus
- Clinical Phase Unknown Postoperative nausea and vomiting
Most Recent Events
- 17 Jul 2026 Launched for Pruritus in China (IV) prior to August 2026 (Haisco Pharmaceutical pipeline, August 2026)
- 17 Jul 2026 Anrikefon is approved for Postoperative pain in orthopedic surgery (Haisco Pharmaceutical pipeline, July 2026)
- 29 Jan 2026 Launched for Postoperative pain in China (Parenteral) prior to January 2026 (Sichuan Haisco Pharmaceutical website, January 2026)